# US 2012/0213817 A1 · Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0213817 A1
- Document ID: US20120213817A1
- Status: Published application
- Kind: A1
- Application number: 13/505,250
- Filed: 2010-11-03
- Published: 2012-08-23
- Earliest claimed: 2009-11-03
- Assignees: Ligocyte Phamaceuticals, Inc.
- Inventors: Joel R. Haynes
- Web page: https://patentgrep.com/patent/US20120213817A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- C07K 16/087: Herpes simplex virus
- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A61K 2039/5258: {Virus-like particles}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C12N 2740/11023: Virus like particles [VLP]
- C12N 2740/16023: Virus like particles [VLP]
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/00023: Virus like particles [VLP]
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.

## Claims

### Claim 1

A chimeric virus-like particle comprising a lentivirus or an alpha-retrovirus Gag polypeptide and a respiratory syncytial virus F polypeptide.

### Claim 2 (depends on 1)

The virus-like particle of claim 1, wherein the Gag polypeptide is from a simian immunodeficiency virus or a human immunodeficiency virus.

### Claim 3 (depends on 1)

The virus-like particle of claim 1, wherein the Gag polypeptide is from an avian leukosis virus or rous sarcoma virus.

### Claim 4 (depends on 1)

The virus-like particle of claim 1, further comprising mammalian glycosylation.

### Claim 5 (depends on 1)

The virus-like particle of claim 1, further comprising an adjuvant in admixture with the virus-like particle.

### Claim 6 (depends on 5)

The virus-like particle of claim 5, wherein the adjuvant is located outside the virus-like particle.

### Claim 7 (depends on 5)

The virus-like particle of claim 5, wherein the adjuvant is located inside the virus-like particle.

### Claim 8 (depends on 1)

The virus-like particle of claim 1, wherein the adjuvant is covalently linked to the respiratory syncytial virus F polypeptide to form a covalent linkage.

### Claim 9 (depends on 1)

The virus-like particle of claim 1, wherein a neutralizing anti-RSV-F antibody binds to the respiratory syncytial virus F polypeptide.

### Claim 10 (depends on 9)

The virus-like particle of claim 9, wherein the neutralizing anti-RSV-F antibody is Palivizumab.

### Claim 11 (depends on 1)

The virus-like particle of claim 1, further comprising an additional VLP-associating antigen.

### Claim 12 (depends on 1)

The virus-like particle of claim 1, further comprising an additional VLP-associating polypeptide linked to a second antigen.

### Claim 13

A method for producing a chimeric virus-like particle, comprising:
(a) providing one or more expression vectors together which express a lentivirus or an alpha-retrovirus Gag polypeptide and a respiratory syncytial virus F polypeptide;
(b) introducing the one or more expression vectors into a eukaryotic cell in a media; and
(c) expressing the Gag polypeptide and the respiratory syncytial virus F polypeptide to produce the chimeric virus-like particle.

### Claim 14 (depends on 13)

The method of claim 13, wherein the eukaryotic cell is a yeast cell, a mammalian cell, or an insect cell.

### Claim 15 (depends on 13)

The method of claim 13, wherein the eukaryotic cell is a mammalian cell.

### Claim at position 16

-17. (canceled)

### Claim 18 (depends on 13)

The method of claim 13, further comprising the step of recovering the virus-like particle from the media in which the eukaryotic cell is cultured.

### Claim 19 (depends on 13)

The method of claim 13, wherein the expression vector is a viral vector.

### Claim 20 (depends on 19)

The method of claim 19, wherein the viral vector is selected from the group consisting of: an adenovirus, a herpesvirus, a poxvirus and a retrovirus.

### Claim 21 (depends on 19)

The method of claim 19, wherein the viral vector further includes a transcriptional regulator that down-regulates expression of the respiratory syncytial virus F polypeptide when the viral vector is propagated in a helper cell or up-regulates expression of the respiratory syncytial virus F polypeptide in the eukaryotic cell.

### Claim 22 (depends on 21)

The method of claim 21, wherein the transcriptional regulator is a tet repressor or a metallothionine inducible enhancer.

### Claim 23 (depends on 13)

The method of claim 13, wherein the eukaryotic cell is selected from the group consisting of a BHK cell, a VERO cell, an HT1080 cell, an MRC-5 cell, a WI 38 cell, an MDCK cell, an MDBK cell, an HEK293 cell, a 293T cell, an RD cell, a COS-7 cell, a CHO cell, a PER.C6™ cell, a Jurkat cell, a HUT cell, a SUPT cell, a C8166 cell, a MOLT4/clone8 cell, an MT-2 cell, an MT-4 cell, an H9 cell, a PM1 cell, a CEM cell, a myeloma cell, SB20 cell, a LtK cell, a HeLa cell, a WI-38 cell, an L2 cell, a CMT-93, and a CEMX174 cell.

### Claim at position 23

-27. (canceled)

### Claim 28 (depends on 1)

A method for treating or preventing respiratory syncytial virus infection comprising administering to a subject an immunogenic amount of the virus-like particle of claim 1.

### Claim at position 25

-30. (canceled)

### Claim 31 (depends on 1)

A pharmaceutical composition comprising an immunogenic amount of the virus-like particle of claim 1.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A method for providing protection against respiratory syncytial virus infection comprising administering to a subject an immunogenic amount of the virus-like particle of claim 1.

### Claim 34

(canceled)
